Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits Reuters Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial ScienceDirect Development of Cagrilintide, a Long Acting Amylin Analogue Journal of Medicinal Chemistry Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Novo Nordisk's share plunges 19.5% post release of weight loss drug CagriSema's trial results Company Business News Novo's Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial BioSpace